Changes in hippocampal metabolites after effective treatment for fibromyalgia: A case study

Clinical Journal of Pain

Volumn 25, Issue 9, 2009, Pages 810-814

  Wood, Patrick B ^a   Ledbetter, Christina R ^b   Patterson, James C ^c,d  

^a Anesthesiology and Psychiatry

^b Toxicology and Neuroscience   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d PET Imaging Center   (United States)

Author keywords

Creatine; Fibromyalgia; Hippocampus; Magnetic resonance spectroscopy; N acetylaspartate; Progesterone; Propranolol; Pyridostigmine

Indexed keywords

3 INDOLEMETHANOL; CREATINE; DIPHENHYDRAMINE; ESTRADIOL; METAXALONE; N ACETYLASPARTIC ACID; PROGESTERONE; PROPRANOLOL; PYRIDOSTIGMINE; TEGASEROD; ZOLPIDEM TARTRATE; ANTIESTROGEN; ASPARTIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIAGNOSTIC AGENT; DRUG DERIVATIVE; INDOLE DERIVATIVE; INDOLE-3-CARBINOL; N-ACETYLASPARTATE; PROTON;

ABDOMINAL TENDERNESS; ADULT; ARTICLE; AUTONOMIC DYSFUNCTION; BATH; BEDTIME DOSAGE; BODY POSITION; BREAST TENDERNESS; CASE REPORT; CASE STUDY; CHRONIC FATIGUE SYNDROME; CHRONIC PAIN; CIRCADIAN RHYTHM; CONSTIPATION; DEPRESSION; DIAPHORESIS; DRUG DOSE INCREASE; DYSMENORRHEA; ESTRADIOL BLOOD LEVEL; FEMALE; FIBROMYALGIA; HIPPOCAMPUS; HORMONAL THERAPY; HUMAN; INSOMNIA; IRRITABILITY; IRRITABLE COLON; JOB STRESS; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NUCLEAR MAGNETIC RESONANCE IMAGING; OVEREXERTION; PARESTHESIA; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RESTLESSNESS; SKIN TINGLING; SLEEP; SLEEP DISORDER; TENSION HEADACHE; TRAFFIC ACCIDENT; WEATHER; XEROSTOMIA; DRUG EFFECT; FOLLOW UP; METABOLISM; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PAIN ASSESSMENT; PATHOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ASPARTIC ACID; CREATINE; ESTROGEN ANTAGONISTS; FEMALE; FIBROMYALGIA; FOLLOW-UP STUDIES; HIPPOCAMPUS; HUMANS; INDOLES; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; PAIN MEASUREMENT; PROPRANOLOL; PROTONS;

EID: 73449118997     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e3181af129e     Document Type: Article

References (34)

1. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160-172.
2. Clauw DJ. Fibromyalgia: more than just a musculoskeletal disease. Am Fam Physician. 1995;52:843-851.
3. Jain AK, Carruthers BM, van de Sande MI, et al. Fibromyal-gia syndrome: Canadian Clinical Working Case Definition, Diagnostic and Treatment Protocols-A Consensus Document. J Musculoskeletal Pain. 2004;11:3-107.
4. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 2007; 87:873-904.
5. Czeh B, Michaelis T, Watanabe T, et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci USA. 2001;98:12796-12801.
6. van der Hart MG, Czeh B, de Biurrun G, et al. Substance P receptor antagonist and clomipramine prevent stress-induced alterations in cerebral metabolites, cytogenesis in the dentate gyrus and hippocampal volume. Mol Psychiatry. 2002;7: 933-941.
7. Wood PB. Fibromyalgia: a central role for the hippocampus, a theoretical construct. J Musculoskeletal Pain. 2004;12:19-26.
8. Ross B, Bluml S. Magnetic resonance spectroscopy of the human brain. Anat Rec. 2001;265:54-84.
9. Emad Y, Ragab Y, Zeinhom F, et al. Hippocampus dysfunction may explain symptoms of fibromyalgia syndrome. A study with single-voxel magnetic resonance spectroscopy. J Rheuma-tol. 2008;35:1371-1377.
10. Wood PB, Ledbetter CR, Broadwell LK, et al. Hippocampal metabolite abnormalities in fibromyalgia: correlation with clinical features. J Pain. 2009;10:47-52.
11. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheu-matol. 1991;18:728-733.
12. Harris RE, Sundgren PC, Pang Y, et al. Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis Rheum. 2008;58:903-907.
13. Petrou M, Harris RE, Foerster BR, et al. Proton MR spectroscopy in the evaluation of cerebral metabolism in patients with fibromyalgia: comparison with healthy controls and correlation with symptom severity. AJNR Am J Neuro-radiol. 2008;29:913-918.
14. Kuchinad A, Schweinhardt P, Seminowicz DA, et al. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain? J Neurosci. 2007; 27:4004-4007.
15. Wood PB, Glabus MF, Simpson R, et al. Changes in gray matter density in fibromyalgia: correlation with dopamine metabolism. J Pain. 2009;10:609-618.
16. Nutt DJ, Malizia AL. Structural and functional brain changes in posttraumatic stress disorder. J Clin Psychiatry. 2004; 65(suppl 1):11-17.
17. Brooks JC, Roberts N, Whitehouse G, et al. Proton magnetic resonance spectroscopy and morphometry of the hippocampus in chronic fatigue syndrome. Br J Radiol. 2000;73:1206-1208.
18. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121:953-959.
19. Martinez-Lavin M, Hermosillo AG, Rosas M, et al. Circadian studies of autonomic nervous balance in patients with fibromyalgia: a heart rate variability analysis. Arthritis Rheum. 1998;41:1966-1971.
20. Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle. 2005;4:1201-1215.
21. Van Houdenhove B, Neerinckx E, Onghena P, et al. Premorbid overactive lifestyle in chronic fatigue syndrome and fibro-myalgia: an etiological relationship or proof of good citizenship? J Psychosom Res. 2001;51:571-576.
22. Karst H, Joels M. Effect of chronic stress on synaptic currents in rat hippocampal dentate gyrus neurons. J Neurophysiol. 2003;89:625-633.
23. Stanton PK, Mody I, Heinemann U. A role for N-methyl-D-aspartate receptors in norepinephrine-induced long-lasting potentiation in the dentate gyrus. Exp Brain Res. 1989;77: 517-530.
24. McKenna JE, Melzack R. Blocking NMDA receptors in the hippocampal dentate gyrus with AP5 produces analgesia in the formalin pain test. Exp Neurol. 2001;72:92-99.
25. Crutcher KA, Davis JN. Hippocampal alpha-and beta-adrenergic receptors: comparison of [3H]dihydroalprenolol and [3H]WB 4101 binding with noradrenergic innervation in the rat. Brain Res. 1980;182:107-117.
26. Hillman KL, Knudson CA, Carr PA, et al. Adrenergic receptor characterization of CA1 hippocampal neurons using real time single cell RT-PCR. Brain Res Mol Brain Res. 2005;139: 267-276.
27. Wood PB, Kablinger AS, Caldito GS. Open trial of pindolol in the treatment of fibromyalgia. Ann Pharmacother. 2005;39: 1812-1816.
28. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive. Pain. 2005;119:5-15.
29. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32:1975-1985.
30. Smith MJ, Adams LF, Schmidt PJ, et al. Effects of ovarian hormones on human cortical excitability. Ann Neurol. 2002; 51:599-603.
31. Bennett RM. Adult growth hormone deficiency in patients with fibromyalgia. Curr Rheumatol Rep. 2002;4:306-312.
32. Cohen H, Neumann L, Alhosshle A, et al. Abnormal sympathovagal balance in men with fibromyalgia. J Rheuma-tol. 2001;28:581-589.
33. Paiva ES, Deodhar A, Jones KD, et al. Impaired growth hormone secretion in fibromyalgia patients: evidence for augmented hypothalamic somatostatin tone. Arthritis Rheum. 2002;46:1344-1350.
34. Bremner JD, Elzinga B, Schmahl C, et al. Structural and functional plasticity of the human brain in posttraumatic stress disorder. Prog Brain Res. 2008;167:171-186.